Estimation of the impact of genital warts on health-related quality of life

被引:99
作者
Woodhall, S. [1 ,2 ]
Ramsey, T. [1 ]
Cai, C. [1 ]
Crouch, S. [2 ]
Jit, M. [3 ]
Birks, Y. [2 ]
Edmunds, W. J. [3 ]
Newton, R. [2 ]
Lacey, C. J. N. [1 ,4 ]
机构
[1] Dept GU Med, Sexual Hlth & HIV Res Unit, York YO31 7WA, N Yorkshire, England
[2] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England
[3] Hlth Protect Agcy, Modelling & Econ Unit, London, England
[4] Univ York, Hull York Med Sch, York, N Yorkshire, England
关键词
D O I
10.1136/sti.2007.029512
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV types 16 and 18. In anticipation of HPV vaccine implementation, the impact of genital warts on health-related quality of life (HRQoL) was measured to assess the potential benefits of the quadrivalent over the bivalent vaccine. Methods: Genitourinary medicine clinic patients aged 18 years and older with a current diagnosis of genital warts were eligible; 81 consented and were interviewed by a member of the research team. A generic HRQoL questionnaire, the EQ-5D (comprising EQ-5D index and EQ visual analogue scale (VAS) scores) and a disease-specific HRQoL instrument, the CECA10, were administered. Previously established UK population norms were used as a control group for EQ-5D comparisons. Results: Cases (with genital warts) had lower EQ VAS and EQ-5D index scores than controls. After adjusting for age a mean difference between cases and controls 30 years of age and under (n = 70) of 13.9 points (95% CI 9.9 to 17.6, p<0.001) for the EQ VAS and 0.039 points (95% CI 0.005 to 0.068, p=0.02) on the EQ-5D index (also adjusted for sex) was observed. The difference between cases and controls for the EQ VAS was especially notable in young women. Conclusions: Genital warts are associated with a significant detriment to HRQoL. The potential added benefit of preventing most cases of genital warts by HPV vaccination should be considered in decisions about which HPV vaccine to implement in the United Kingdom.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 30 条
[1]
Combination of qualitative and quantitative methods for developing a new Health Related Quality of Life measure for patients with anogenital warts [J].
Badia X. ;
Colombo J.A. ;
Lara N. ;
Llorens M.A. ;
Olmos L. ;
de los Terreros M.S. ;
Varela J.A. ;
Vilata J.J. .
Health and Quality of Life Outcomes, 3 (1)
[2]
Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
[3]
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada [J].
Brisson, Marc ;
Van de Velde, Nicolas ;
De Wals, Philippe ;
Boily, Marie-Claude .
VACCINE, 2007, 25 (29) :5399-5408
[4]
Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients [J].
Brown, DR ;
Schroeder, JM ;
Bryan, JT ;
Stoler, MH ;
Fife, KH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (10) :3316-3322
[5]
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK [J].
Brown, R. E. ;
Breugelmans, J. G. ;
Theodoratou, D. ;
Benard, S. .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (04) :663-670
[6]
A catalog of dermatology utilities: A measure of the burden of skin diseases [J].
Chen, SC ;
Bayoumi, AM ;
Soon, SL ;
Aftergut, K ;
Cruz, P ;
Sexton, SA ;
McCall, CO ;
Goldstein, MK .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2004, 9 (02) :160-168
[7]
A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus [J].
Conaglen, HM ;
Hughes, R ;
Conaglen, JV ;
Morgan, J .
INTERNATIONAL JOURNAL OF STD & AIDS, 2001, 12 (10) :651-658
[8]
*DEP HLTH, 2007, HIV VACC REC NHS IMM
[9]
*HLTH PROT AG, 1997, ALL NEW STI EP SEEN
[10]
*HLTH PROT AG, 2006 STI DAT